ArticleKidney research and clinical practice2024

Efficacy and cost-effectiveness of darbepoetin alfa once every 4 weeks versus continuous erythropoietin receptor activator once every 4 weeks for anemia correction in patients with chronic kidney disease not on dialysis.

Geo Neul Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.